Literature DB >> 22946869

Continuous infusion of antibiotics in critically ill patients.

Piotr Smuszkiewicz1, Edyta Szałek, Hanna Tomczak, Edmund Grześkowiak.   

Abstract

Antibiotics are the most commonly used drugs in intensive care unit patients and their supply should be based on pharmacokinetic/pharmacodynamic rules. The changes that occur in septic patients who are critically ill may be responsible for subtherapeutic antibiotic concentrations leading to poorer clinical outcomes. Evolving in time the disturbed pathophysiology in severe sepsis (high cardiac output, glomerular hyperfiltration) and therapeutic interventions (e.g. haemodynamically active drugs, mechanical ventilation, renal replacement therapy) alters antibiotic pharmacokinetics mainly through an increase in the volume of distribution and altered drug clearance. The lack of new and efficacious drugs and increased bacterial resistance are current problems of contemporary antibiotic therapy. Although intermittent administration is a standard clinical practice, alternative methods of antibiotic administration are sought, which may potentialise effects and reduce toxicity as well as contribute to inhibition of bacterial resistance. A wide range of studies prove that the application of continuous infusion of time-dependent antibiotics (beta-lactams, glycopeptides) is more rational than standard intermittent administration. However, there are also studies which do not confirm the advantage of one method over the other. In spite of controversy the continuous administration of this group of antibiotics is common practice, because the results of both studies point to the higher efficacy of this method in critically ill patients. Authors reviewed the literature to determine whether any clinical benefits exist for administration of time-dependent antibiotics by continuous infusion. Definite specification of the clinical advantage of administration this way over standard dosage requires a large-scale multi-centre randomised controlled trial.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22946869     DOI: 10.2174/1574884711308010004

Source DB:  PubMed          Journal:  Curr Clin Pharmacol        ISSN: 1574-8847


  6 in total

Review 1.  [Pharmacokinetic and pharmacodynamic aspects in antibiotic treatment].

Authors:  R Bellmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-03-20       Impact factor: 0.840

Review 2.  Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.

Authors:  Mordechai Grupper; Joseph L Kuti; David P Nicolau
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

Review 3.  Future Challenges in Pediatric and Neonatal Sepsis: Emerging Pathogens and Antimicrobial Resistance.

Authors:  Laura Folgori; Julia Bielicki
Journal:  J Pediatr Intensive Care       Date:  2019-01-17

Review 4.  [Personalised pharmacotherapy in intensive care unit patients].

Authors:  R Bellmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-05-02       Impact factor: 0.840

5.  Optimizing the Use of Antibacterial Agents in the Neonatal Period.

Authors:  Joseph B Cantey
Journal:  Paediatr Drugs       Date:  2016-04       Impact factor: 3.022

Review 6.  Effects of continuous renal replacement therapy on linezolid pharmacokinetic/pharmacodynamics: a systematic review.

Authors:  Gianluca Villa; Paola Di Maggio; A Raffaele De Gaudio; Andrea Novelli; Riccardo Antoniotti; Enrico Fiaccadori; Chiara Adembri
Journal:  Crit Care       Date:  2016-11-19       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.